Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation

Clinical Immunology

Volumn 132, Issue 2, 2009, Pages 222-233

  MacMillan, Heather F ^a   Lee, Tim ^a   Issekutz, Andrew C ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Immunoregulation; ; Immunosuppression; ; Intravenous IgG; IVIG; ; Lymphocyte;

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; THYMIDINE;

ACCESSORY CELL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 67649945841     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.04.002     Document Type: Article

References (32)

1. Cunningham-Rundles C., Hanson L.A., Hitzig W.H., Knapp W., Lambert P.-H., Nydegger U.E., Prince A.M., Rosen F.S., Seligmann M., Soothill J.F., Thompson R.A., Torrigiani G., and Wedgwood R.J. Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting. Bull. World Health Organ. 60 (1982) 43-47
2. Imbach P., Barandun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., Rossi E., Schoni M., Vest M., and Wagner H.P. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1 (1981) 1228-1231
3. Negi V.S., Elluru S., Siberil S., Graff-Dubois S., Mouthon L., Kazatchkine M.D., Lacroix-Desmazes S., Bayry J., and Kaveri S.V. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol. 27 (2007) 233-245
4. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., Buckley R., Chinen J., El-Gamal Y., Mazer B.D., Nelson Jr. R.P., Patel D.D., Secord E., Sorensen R.U., Wasserman R.L., and Cunningham-Rundles C. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 117 (2006) S525-553
5. Darabi K., Abdel-Wahab O., and Dzik W.H. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 46 (2006) 741-753
6. Bayry J., Kazatchkine M.D., and Kaveri S.V. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat. Clin. Pract. Neurol. 3 (2007) 120-121
7. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345 (2001) 747-755
8. Simon H.U., and Spath P.J. IVIG-mechanisms of action. Allergy 58 (2003) 543-552
9. Nimmerjahn F., and Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26 (2008) 513-533
10. Kawada K., and Terasaki P.I. Evidence for immunosuppression by high-dose gammaglobulin. Exp. Hematol. 15 (1987) 133-136
11. van Schaik I.N., Lundkvist I., Vermeulen M., and Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J. Clin. Immunol. 12 (1992) 325-334
12. Amran D., Renz H., Lack G., Bradley K., and Gelfand E.W. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin. Immunol. Immunopathol. 73 (1994) 180-186
13. Schanz U., Hugle T., and Gmur J. Additional inhibitory effects of intravenous immunoglobulins in combination with cyclosporine A on human T lymphocyte alloproliferative response in vitro. Transplantation 61 (1996) 1736-1740
14. Skansen-Saphir U., Andersson J., Bjork L., Ekberg C., Fehniger T.E., Henter J.I., and Andersson U. Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells. Scand. J. Immunol. 47 (1998) 229-235
15. Bayry J., Lacroix-Desmazes S., Carbonneil C., Misra N., Donkova V., Pashov A., Chevailler A., Mouthon L., Weill B., Bruneval P., Kazatchkine M.D., and Kaveri S.V. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101 (2003) 758-765
16. Tha-In T., Metselaar H.J., Tilanus H.W., Groothuismink Z.M., Kuipers E.J., de Man R.A., and Kwekkeboom J. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood 110 (2007) 3253-3262
17. Bayry J., Lacroix-Desmazes S., Delignat S., Mouthon L., Weill B., Kazatchkine M.D., and Kaveri S.V. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum. 48 (2003) 3497-3502
18. Nel A.E. T-cell activation through the antigen receptor. Part 1: Signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse. J. Allergy Clin. Immunol. 109 (2002) 758-770
19. Nel A.E., and Slaughter N. T-cell activation through the antigen receptor. Part 2: Role of signaling cascades in T-cell differentiation, anergy, immune senescence, and development of immunotherapy. J. Allergy Clin. Immunol. 109 (2002) 901-915
20. Clark D.A., Wong K., Banwatt D., Chen Z., Liu J., Lee L., Gorczynski R.M., and Blajchman M.A. CD200-dependent and nonCD200-dependent pathways of NK cell suppression by human IVIG. J. Assist. Reprod. Genet. 25 (2008) 67-72
21. Borriello F., Lederer J., Scott S., and Sharpe A.H. MRC OX-2 defines a novel T cell costimulatory pathway. J. Immunol. 158 (1997) 4548-4554
22. Gorczynski R.M., Yu K., and Clark D. Receptor engagement on cells expressing a ligand for the tolerance-inducing molecule OX2 induces an immunoregulatory population that inhibits alloreactivity in vitro and in vivo. J. Immunol. 165 (2000) 4854-4860
23. Cohen I.R., and Cooke A. Natural autoantibodies might prevent autoimmune disease. Immunol. Today 7 (1986) 363-364
24. Quintana F.J., and Cohen I.R. The natural autoantibody repertoire and autoimmune disease. Biomed. Pharmacother. 58 (2004) 276-281
25. Marchalonis J.J., Kaymaz H., Dedeoglu F., Schluter S.F., Yocum D.E., and Edmundson A.B. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 3325-3329
26. Hurez V., Kaveri S.V., Mouhoub A., Dietrich G., Mani J.C., Klatzmann D., and Kazatchkine M.D. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther. Immunol. 1 (1994) 269-277
27. Bayry J., Lacroix-Desmazes S., Donkova-Petrini V., Carbonneil C., Misra N., Lepelletier Y., Delignat S., Varambally S., Oksenhendler E., Levy Y., Debre M., Kazatchkine M.D., Hermine O., and Kaveri S.V. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14210-14215
28. Notkins A.L., and Prabhakar B.S. Monoclonal autoantibodies that react with multiple organs. Basis for reactivity. Ann. N. Y. Acad. Sci. 475 (1986) 123-134
29. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol. Today 12 (1991) 154-159
30. Kersh G.J., and Allen P.M. Essential flexibility in the T-cell recognition of antigen. Nature 380 (1996) 495-498
31. Germain R.N., and Stefanova I. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu. Rev. Immunol. 17 (1999) 467-522
32. Kessel A., Ammuri H., Peri R., Pavlotzky E.R., Blank M., Shoenfeld Y., and Toubi E. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J. Immunol. 179 (2007) 5571-5575